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Purpose: Curcumin, a plant-derived natural polyphenol, could be a promising anti-cancer 
drug and shows synergic effects with cytotoxic agents. We evaluated the safety and 
feasibility of complementary therapy using curcumin with gemcitabine-based chemotherapy. 
Methods: Gemcitabine-resistant patients with pancreatic cancer received 8 g oral curcumin 
daily in combination with gemcitabine-based chemotherapy. The primary endpoint was 
safety for phase I and feasibility of oral curcumin for phase II study. 
Results: Twenty-one patients were enrolled. No dose-limiting toxicities were observed in 
the phase I study and oral curcumin 8 g/day was selected as the recommended dose for the 
phase II study. No patients were withdrawn from this study because of the intolerability of 
curcumin, which met the primary endpoint of the phase II study, and the median compliance 
rate of oral curcumin was 100% (Range 79–100%). Median survival time after initiation of 
curcumin was 161 days (95% confidence interval 109–223 days) and 1-year survival rate 
was 19% (4.4–41.4%). Plasma curcumin levels ranged from 29 to 412 ng/ml in five patients 
tested.  
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Conclusions: Complementary therapy using 8 g oral curcumin daily with 
gemcitabine-based chemotherapy was safe and feasible in patients with pancreatic cancer 
and warrants further investigation of its efficacy.  
Key words: curcumin, gemcitabine, pancreatic cancer 




Pancreatic cancer is one of the most lethal malignancies worldwide [9, 15]. Although surgery 
remains the only modality to potentially cure this disease, most patients are diagnosed too 
late for curative resection. Even after potentially curative resection, this disease relapses in 
more than 80% of patients and incidence rates are almost coincident with mortality rates [18]. 
Over the past decade, gemcitabine has been widely used as a standard therapy for 
advanced pancreatic cancer. Gemcitabine has been proved to improve the median survival 
time and quality of life in advanced pancreatic cancer patients [4]; however, the prognosis of 
this disease remains dismal and the development of more effective therapy is urgently 
needed. Because pancreatic cancer patients often suffer from symptoms related to the 
cancer itself (e.g. fatigue, appetite loss, pain), it is also very important to maintain a balance 
between efficacy and quality of life in palliative chemotherapy for pancreatic cancer.  
Curcumin is derived from turmeric (Curcuma longa) and is a natural polyphenol. Curcumin 
has long been used as a food, coloring agents or a traditional medicine. More and more data 
support the idea that this chemical could be a promising anti-cancer drug for a variety of 
tumors [6, 10, 19, 23]. Preclinical studies demonstrated curcumin potentiates antitumor 
activity of gemcitabine against pancreatic cancer [2, 14]. Human studies of curcumin have 
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shown that this agent can be administered safely at doses of up to 12 g/day [5, 21] and 
some clinical benefit in patients with pancreatic cancer [7]. Thus, synergic effects of 
curcumin on gemcitabine in preclinical studies and safety of curcumin monotherapy in 
clinical studies have been reported; however, at the time of planning this clinical trial in 2008, 
the safety and feasibility of curcumin in combination with gemcitabine-based chemotherapy 
had not been reported in a human study. Because the clinical condition of pancreatic cancer 
patients who failed gemcitabine-based chemotherapy was generally poor, we needed to 
evaluate whether these patients could tolerate a large amount of daily oral curcumin in 
combination with gemcitabine-based chemotherapy. Therefore we conducted this phase I/II 
study to determine the safety and feasibility of oral curcumin in combination with 
gemcitabine-based chemotherapy in patients with pancreatic cancer. 
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Patients and methods 
Eligibility criteria 
Patients with advanced pancreatic cancer who showed disease progression during 
gemcitabine-based chemotherapy and had no other effective treatment option were eligible 
if they met the following criteria: histological or radiological confirmation; age ≥20 years; 
Eastern Cooperative Oncology Group (ECOG) performance status of 0–1; bone marrow 
function (neutrophil count ≥1500/mm3 and platelet count ≥100,000/mm3), liver function (total 
bilirubin ≤3 times the upper limit of normal (ULN) and aspartate aminotransferase/alanine 
aminotransferase (AST/ALT) ≤5 times ULN) and renal function (creatinine ≤1.5 mg/dL); 
adequate oral intake; and provided written informed consent. A criterion of neutrophil count 
/platelet count was amended to ≥1000/mm3/≥50,000/mm3, respectively, after confirming 
safety of curcumin in phase I study.  Exclusion criteria included: history of severe drug 
allergy; pregnancy or lactation; and other severe comorbid diseases. 
This phase I/II study (UMIN ID 000001386) was conducted in two institutions in Japan. The 
protocol was approved by the institutional review board at each institution and patient 
registration and data management were conducted in an independent data center at 
Translational Research Center, Kyoto University Hospital. All procedures were performed in 
accordance with the 1964 Declaration of Helsinki. 




Curcumin was courteously provided by the Sabinsa Corporation (Piscataway, NJ, USA) in 
microbead form. One gram of curcuminoids consisted of 900 mg of curcumin, 80 mg of 
desmethoxycurcumin, and 20 mg of bisdesmethoxycurcumin, which was confirmed by 
high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) as 
reported previously [7]. 
Treatment 
As an initial dose level, oral curcumin daily with a dose of 8 g was chosen according to the 
previous human studies [5, 7, 21]. Oral curcumin was added to the gemcitabine-based 
chemotherapy (19 patients received gemcitabine/S-1 combination therapy and two patients 
received gemcitabine monotherapy). Patients were allowed to take 8 g of curcumin 
separately at their own convenience. The same dose and schedule of gemcitabine-based 
chemotherapy were applied as used before enrollment onto this study. After the initiation of 
curcumin intake, the dose and schedule of gemcitabine-based chemotherapy was adjusted 
at the discretion of individual physicians according to the adverse events observed in the 
previous cycle. Dose-limiting toxicity (DLT) for the phase I study was defined as follows: 
Grade 4 leucopenia; Grade 4 neutropenia; Grade 3 or more thrombocytopenia; 
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non-hematological toxicity of Grade 3 or more (except for the abnormal blood test); patient 
refusal due to the intolerability of curcumin intake. No dose escalation was planned and 
dose de-escalation to 6 g/day was pre-planned if more than one DLT among three 
assessable patients or more than two DLTs among six assessable patients were observed. 
Chemotherapy was suspended until recovery if neutrophil count was <1000/mm3, platelet 
count was <70,000/mm3, total bilirubin was >3.0 mg/dL, AST/ALT was >150 U/L, creatinine 
was >1.5 mg/dL, stomatitis/diarrhea was Grade 2 or higher, skin rash was Grade 3 or higher, 
or there was a fever (>38℃) due to infection. During the suspension of gemcitabine-based 
chemotherapy, curcumin intake was also suspended. The study treatment was continued 
until intolerability of curcumin intake, unacceptable toxicity related to treatment, patient 
refusal, or discontinuation of gemcitabine-based chemotherapy because of deterioration of 
general condition due to disease progression occurred. 
Pretreatment and follow-up evaluation 
Pretreatment evaluation included obtaining the patient’s medical history and performing a 
physical examination, imaging using contrast-enhanced computed tomography (CT) or 
magnetic resonance imaging (MRI), a complete blood cell count, and serum biochemical 
tests. Physical examinations and blood tests were scheduled on the day of gemcitabine 
administration. Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) 
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were measured every month. Toxicity was evaluated using the National Cancer Institute 
Common Toxicity Criteria version 3.0 [25]. 
Sample preparation and measurement of plasma curcumin levels by HPLC-MS/MS 
Despite the use of doses of curcumin as high as 8 g/day, previous studies reported very little 
free curcumin is found in patient plasma samples [21]. Instead, curcumin is present in 
plasma in conjugated (glucuronide and sulfate) forms, which necessitates appropriate 
enzymatic hydrolysis of the plasma before detection of free curcumin [7, 26]. In the present 
study we measured plasma curcumin levels in five patients who provided written informed 
consent for blood draws for this purpose. A 0.1 mL aliquot of each plasma sample was 
transferred to a 10 mL glass tube and then 0.11 mL of 0.1 M sodium acetate buffer (pH 5.0) 
containing 1000 U β-glucuronidase was added. The resulting solutions were incubated to 
hydrolyze the curcumin conjugates at 37°C for 1 h. After 10 µL of Internal Standard (IS) 
working solution (500 ng/mL) was added, 0.5 mL of chloroform as extraction solvent was 
added. The sample was vortexed for 1 min followed by ultrasonic vibrations for 15 min and 
then centrifugation at 1610×g for 5 min. The organic layer was transferred to a 1 mL glass 
tube and evaporated to dryness using a centrifuge concentrator. The dried extract was 
reconstituted in 100 µL of 50% acetonitrile containing 0.05% formic acid (FA) and then 
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centrifugated at 7700×g for 10 min. A 10 µL aliquot of supernatant of reconstituted sample 
solution was injected into the chromatographic system. 
The HPLC-MS/MS system consisted of a Prominence micro-LC system (Shimadzu, Kyoto, 
Japan) and an API 3200 tandem mass spectrometer (Applied Biosystems, Carlsbad, CA, 
USA) with (+) electrospray ionization (ESI). Samples were put through an Atlantis T3 
(2.1×150 mm, 3 µm) (Waters, Milford, USA) C-18 separation column using a gradient of 
binding solvent (0.05% FA/water) and elution solvent (0.05% FA/acetonitrile) at a flow rate 
of 0.2 mL/min and a column temperature of 40°C. Separation of samples was conducted by 
a 35 min linear gradient (5–95% elution solvent). The mass spectrometer was operated 
under multiple reaction monitoring (MRM) mode with collision energy of 23 eV for curcumin 
and 33 eV for mepronil. The transitions (precursor to product) monitored were m/z 369→285 
for curcumin and 270→119 for mepronil. Chromatograms were integrated using ANALYST 
software, version 1.5.Stock solutions of curcumin and mepronil were prepared at a 
concentration of 1000 ng/mL in methanol. The stock solution of mepronil was further diluted 
with 55% methanol to prepare a calibration standard at a concentration of 100 ng/mL. The 
stock solution of curcumin was further diluted with 62% methanol to prepare a calibration 
standard at a concentration of 200 ng/mL. Curcumin solution (200 ng/mL) was diluted with 
50% methanol to prepare the following standard solutions: 0.4, 0.8, 1.6, 3.1, 6.3, 12.5, 25.0, 
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50.0, and 100.0 ng/mL. These solutions were mixed with IS solution (100 ng/mL) at a ratio of 
1:1 to prepare IS-containing calibration samples of 0.2–100.0 ng/mL (curcumin) and 50 
ng/mL (mepronil). Stock solution (1000 ng/mL) of mepronil was further diluted with methanol 
to prepare the IS working solution at a concentration of 500 ng/mL. 
Statistical analysis 
The primary endpoint was safety for the phase I study and treatment completion rate (TCR) 
of oral curcumin daily at dose of 8 g for the phase II study. TCR was defined as the 
percentage of patients after excluding those who were withdrawn from this study because of 
the intolerability of curcumin. The secondary endpoints for phase II were response 
rate,overall survival (OS) and compliance rate of curcumin. We considered if less than 50% 
of patients could tolerate complementary therapy using curcumin, this therapy was not worth 
for further evaluation. If 80% or more patients could continue this therapy without any 
clinically relevant toxicity, this therapy was considered to be worth for further evaluation of its 
efficacy. Therefore, a sample size of 21 patients for phase II was determined to reject the 
null hypothesis of a TCR of 50% under the expectations of 80% TCR with a significance 
level of 0.05 and a power of 80%. Among patients with measurable target lesions, the 
objective response rate was evaluated according to Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.0 [24]. OS was defined as the time from initiation of 
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complementary therapy using curcumin to death from any cause or the final follow-up, and 
OS rate was calculated using the Kaplan-Meier method. The final analysis was conducted in 
April 2010. All analyses were conducted on an intention-to-treat basis and were performed 
using SAS version 9.2 (SAS Institute, Cary, NC, USA). 
 





Twenty-one patients were enrolled between September 2008 and August 2009. The patient 
characteristics are shown in Table 1. The median age was 67 years (range 44–79 years) 
and 13 patients (62%) were men. Seven of the 21 patients (33%) experienced recurrent 
disease after undergoing curative surgery and three patients had a history of radiotherapy. 
All the patients had a history of receiving gemcitabine and S-1. Oral curcumin was added to 
gemcitabine/S-1 combination therapy in 19 patients (90%) and gemcitabine monotherapy in 
two patients (10%). 
Toxicity 
In the phase I study, safety of oral curcumin taken daily at dose of 8 g in combination with 
gemcitabine-based chemotherapy was evaluated. Since the first three assessable patients 
completed their first cycle without a DLT at 8 g/day, we selected this amount as the 
recommended dose for the following phase II study. Overall adverse events are summarized 
in Table 2. The most common grade 3-4 hematological toxicity was neutropenia (38%) and 
grade 3-4 non-hematological toxicity was fatigue (10%), both of which were likely to be 
attributed to the gemcitabine-based chemotherapy or disease progression and considered 
to be irrelevant to curcumin. Other Grade 3–4 non-hematological adverse events were a 
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drowsiness (n=1), an anorexia (n=1), an obstruction of gastrointestinal tract (n=1), and an 
edema (n=1), all of which were also attributed to disease progression. 
Treatment completion rate and compliance rate of curcumin 
No patients were withdrawn from this study because of the intolerability of curcumin, yielding 
a TCR of 100% (95% confidence interval (CI) 84–100%; P<0.001 under the null hypothesis 
of a 50% TCR).  At the time of final analysis in April 2010, two patients were still on protocol 
treatment and the reasons for discontinuation of protocol treatment were disease 
progression (n=12), adverse events unrelated to curcumin intake (n=3), judgment of 
physician (n=1), referral to another hospital (n=1), patient`s request (n=1) and protocol 
violation (n=1). Compliance rate of curcumin is summarized in Table 3. In spite of the high 
amount required to be taken, 19 patients (90%) were able to take more than 90% of the 
curcumin scheduled in this clinical trial. 
Efficacy 
Seventeen patients (81%) died during the study period. The median overall survival time 
was 161 days (95% CI 109–223 days) and 1-year survival rate was 19% (95% CI 
4.4–41.4%)(Figure 1). Among eighteen evaluable patients, no patients experienced a partial 
or complete response and five patients (28%) demonstrated stable disease according to 
RECIST. Median time to treatment failure was 71 days (95% CI 58–126 days)(Figure 2).  




Plasma curcumin levels were measured in five patients. We measured curcumin levels 
following digestion of plasma with combined glucuronidase and sulfatase enzymes. The 
data on plasma curcumin levels and information about duration of curcumin intake and time 
of blood draw after final curcumin intake are summarized in Table 4. Except for one patient 
who demonstrated a plasma curcumin level of 412 ng/ml, curcumin levels ranged from 29 to 
91 ng/ml, which was comparable with the previous study [7, 21]. 




Curcumin has been reported to modulate a variety of molecules which play an important role 
in cancer progression. One of the major targets of curcumin is NF-κB, which regulates the 
expression of a number of genes involved in antiapoptosis (Bcl-2, Bcl-xL), proliferation 
(cyclin D1, c-myc), angiogenesis (vascular endothelial growth factor (VEGF), interleukin-8), 
and invasion (matrix metalloproteinases) [1, 11, 13, 16]. Several preclinical studies have 
also reported the synergic effect of curcumin in combination with cytotoxic agents. Synergic 
inhibitory effects of curcumin and 5-fluorouracil on the growth of cancer cell lines have been 
demonstrated [8, 12]. Vinorelbine-mediated apoptosis is also enhanced by curcumin in 
squamous lung cancer cell line [20]. Kunnumakkara et al. demonstrated that curcumin 
potentiates the antitumor effects of gemcitabine in pancreatic cancer and suppresses 
NF-κB-regulated genes in vitro and in vivo [14]; however, we have no data about the safety 
and feasibility of curcumin in combination with gemcitabine-based chemotherapy in human 
studies and we conducted current study to evaluate whether pancreatic patients could 
tolerate large amount of daily oral curcumin in combination with gemcitabine-based 
chemotherapy. The toxicity profile of this study was comparable with that observed in 
pancreatic cancer patients treated with gemcitabine/S-1 combination therapy [29]. Therefore, 
we considered adding oral curcumin to gemcitabine-based chemotherapy did not increase 
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the risk of clinically relevant toxicity. No patients were withdrawn from this study because of 
the intolerability of curcumin and a high compliance rate was achieved in spite of the poor 
clinical condition after failure of gemcitabine-based chemotherapy. In fact, the median 
compliance rate of oral curcumin was 100% (range 79–100%), as shown in Table 3, which 
strongly supported the minimal toxicity of this agent in cancer patients who were receiving 
concomitant chemotherapy. Furthermore, cumulative toxicity of curcumin was not observed 
in this study and four patients could continue curcumin intake for more than 6 months 
without any significant toxicity, which supports the safety of this agent for long-term use. 
Since pancreatic cancer patients suffer from symptoms related to cancer itself, the low 
toxicity of this agent is a great advantage for its clinical application in cancer treatment. 
Some previous clinical studies indicated the risk of diarrhea with curcumin intake [10, 21]. In 
our study, among four cases of grade 1 diarrhea, two cases could have been attributed to 
curcumin, but this did not interrupt curcumin intake or gemcitabine-based chemotherapy. 
We speculated that allowing patients to take curcumin separately reduced the risk of 
osmotic diarrhea caused by large amounts of curcumin taken at once. Another possible 
explanation was that patients with pancreatic cancer often suffered from constipation due to 
peritonitis carcinomatosa or side effect of taking morphine and these backgrounds might 
have attenuated the risk of diarrhea. In consistent with our current study, Bayet-Robert et al. 
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recently conducted phase I study of docetaxel plus curcumin in breast cancer patients and 
reported the safety of oral curcumin at a dose of 6 g/day for 7 consecutive days every 3 
weeks [3]. 
 As Oettle et al. reported that median survival time after failure of first-line gemcitabine 
therapy was only 10 weeks in patients receiving best supportive care alone [17], the 
prognosis of pancreatic cancer patients who failed gemcitabine-based chemotherapy was 
very poor. Therefore, a median survival time of 161 days (95% CI 109–223 days) and a 
1-year survival rate of 19% (95% CI 4.4–41.4%) in our current study were encouraging and 
warranted further investigation. Interestingly, several patients reported an improvement of 
cancer- or chemotherapy-related symptoms (e.g. fatigue, pain, constipation) after the 
initiation of curcumin intake. Unfortunately the quality-of-life score was not included in the 
pre-specified endpoints in our current study and these changes might be solely attributed to 
placebo effects; however, data from several basic studies support our current observation. 
Curcumin has been shown to improve depressive-like behaviors in mice with an increase in 
serotonin, noradrenaline, and dopamine levels in the brain [27, 28] or attenuate 
hyperalgesia in a mouse model of neuropathic pain [22]. It is very important to maintain 
quality of life in palliative chemotherapy for pancreatic cancer and the improvement of 
cancer- or chemotherapy-related symptoms could increase the compliance to chemotherapy, 
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which largely affects the efficacy of chemotherapy and overall survival. More clinical trials 
are needed to determine the efficacy of curcumin from viewpoint of quality of life in cancer 
patients. 
Plasma curcumin levels were measured in five patients. Except for one patient, our current 
results were almost consistent with a previous study reporting that steady-state curcumin 
level ranged from 22 to 41 ng/ml [7]. Furthermore, current results demonstrated a 
cumulative increase in curcumin levels was unlikely after long-term intake. Poor 
bioavailability is the major weak point of curcumin when considering its clinical application. 
Since basic studies suggested that a microgram range of curcumin in target tissue is 
necessary to achieve anti-cancer effects, many researchers are focusing on improving the 
bioavailability of curcumin to get more benefits from this promising agent. Recently, 
pulverized curcumin was developed in Japan (Theravalues Corporation, Tokyo, Japan) to 
improve the agent’s bioavailability. If we could achieve higher plasma curcumin levels, we 
could expect more benefits from curcumin in the treatment of cancer patients and we are 
now planning clinical trials to evaluate the efficacy of this newly developed curcumin.  
In conclusion, our data demonstrated that administration of oral curcumin in combination 
with gemcitabine-based chemotherapy is safe and well-tolerated in pancreatic cancer 
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Table 1. Patient characteristics (n=21) 
 
Gender Male 13 (62.0%) 
 Female 8 (38.0%) 
Age (years) Median  67 
 Range 44–79 
Diagnosis Histological confirmation 19 (90.0%) 
 Imaging test 2 (10.0%) 
History of anti-cancer drugs Gemcitabine  21 (100.0%) 
 S-1 21 (100.0%) 
History of surgery  7 (33%) 
History of radiotherapy  3 (14%) 
Concomitant chemotherapy  Gemcitabine/S-1  19 (90%) 
 Gemcitabine 2 (10%) 
 




Table 2. Toxicity 
 
  Grade 1 Grade 2 Grade 3 Grade 4 ≧Grade 3 ≧Grade 
1–4 
Fatigue 7 3 2 0 10% 57% 
Anorexia 5 2 1 0 5% 38% 
Diarrhea 4 0 0 0 0% 19% 
Hand-foot 
rash 
4 0 0 – 0% 19% 
Stomatitis 3 0 0 0 0% 14% 
Nausea 2 0 0 0 0% 10% 
Vomiting 1 0 0 0 0% 5% 
Leukocytes 1 5 7 0 33% 62% 
Neutrophil 0 4 8 0 38% 57% 
Hemoglobin 3 9 4 0 19% 76% 
Platelets 4 3 2 0 10% 43% 
Bilirubin 7 2 1 1 10% 52% 
AST 14 0 0 0 0% 67% 
ALT 7 2 0 0 0% 43% 
Creatinine 3 1 0 0 0% 19% 
Albumin 9 9 0 0 0% 86% 
ALP 11 4 0 0 0% 71% 
Others 
(≧Grade 3) – – 4 0 19% – 
 




Table 3. Compliance rate 
 
Compliance Rate (n=21)   
<0.70 0 
>0.70, <0.80 1 
>0.80, <0.90 1 
>0.90, <0.95 1 
>0.95, <1.00 4 
1.00  14 
Compliance rate>0.90 90% 
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Table 4. Plasma curcumin levels and patient information 
 




curcumin intake  
Plasma curcumin 
levels (ng/ml) 
Time of blood draw after 
final curcumin intake 
(hours) 
Case 1 69 Female 14 months 29 24 
Case 2 75 Male 4 months 55 4 
Case 3 67 Female 6 months 85 1 
Case 4 75 Female 6 months 91 9 
Case 5 70 Male 3 months 412 4 
 
 




Figure 1. Overall survival (n=21) 





















(95% CI; 109-223 days)
Page 27 of 33 Cancer Chemotherapy and Pharmacology
27 
 
Figure 2. Time to treatment failure (n=21) 























(95% CI; 58-126 days)
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